Introduction Automated insulin delivery systems (AID) are the preferred treatment modality for type 1 diabetes (T1D) because use improves time in range (TIR), reduces hypoglycemia, and helps to ease the burden of diabetes (1, 2). In the last year, the results of clinical trials demonstrating the efficacy of AID in individuals with type 2 diabetes (T2D) have further expanded indications for AID use (1, 3, 4). However, AID remains underutilized (5).
Brynn E. Marks
As seen in:
Frontiers,
The Lancet,
Mary Ann Liebert, Inc.,
Healio,
Endocrine Today,
Clinics in Chest Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Brynn E.
Contact Brynn E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack